Xeljanz is an oral prescription medication approved to treat moderately to severely active rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. It also comes in an extended-release formulation, Xeljanz XR.

Xeljanz and Xeljanz XR are made by Pfizer Inc., a pharmaceutical company located in New York, NY.

Tofacitinib is a prescription medication used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, and Ankylosing Spondylitis. Tofacitinib is available under the following different brand names: Xeljanz, Xeljanz XR.

Tofacitinib, also known as Xeljanz, is a type of drug known as a Janus kinase (JAK) inhibitor. It works by blocking the action of Janus kinase enzymes, which are involved in the inflammation that causes the symptoms of rheumatoid arthritis and psoriatic arthritis.

Development timeline for Xeljanz

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis.

Xeljanz contains the drug tofacitinib. It belongs to a class of drugs called Janus kinase inhibitors. These drugs help to decrease inflammation in your body. Xeljanz comes as a tablet and solution that's taken by mouth.

Over the course of 20 years Pfizer invested more than $1 billion into the discovery, development and commercialization of Xeljanz.

As the developer of XELJANZ/XELJANZ XR, Pfizer is a leader in JAK innovation.

Generic Name: tofacitinib Tofacitinib is used to treat certain types of arthritis (such as psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis-pcJIA).

Tofacitinib is a prescription medication used to treat Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, and Ankylosing Spondylitis. Tofacitinib is available under the following different brand names: Xeljanz, Xeljanz XR.

About XELJANZ® (tofacitinib) XELJANZ has been studied in more than 50 clinical trials worldwide, including more than 20 trials in RA patients, and prescribed to over 300,000 adult patients (the majority of whom were RA patients) worldwide since 2012.